Eli Lilly's weight-loss drug Zepbound showed promise for treating sleep apnea — giving investors more confidence to proceed owning the world's most useful health care company even after it squeezed the S&P 500's performance over the past three years had. Study results released Wednesday by Eli Lilly underscore the range of health advantages that drugs like Lilly's Zepbound and Mounjaro — often known as GLP-1 — can have beyond their increasingly popular uses in treating obesity and sort 2 diabetes. Lilly can be studying GLP-1 to scale back the danger of cardiovascular events similar to heart attacks and strokes, in addition to a form of fatty liver disease. Lilly's essential competitor within the category, Novo Nordisk, recently received US approval to market its obesity drug Wegovy as a treatment for heart disease in obese patients. Novo Nordisk was the primary to bring to market the GLP-1 products Wegovy and Ozempic for diabetes. Although Ozempic is a diabetes drug, it has develop into the general public face of this emerging class of medicine that also leads to significant weight reduction. Eli Lilly said it plans to ask U.S. regulators later this 12 months to expand Zepbound's labeling to incorporate obstructive sleep apnea (OSA). OSA is considered one of the three commonest kinds of sleep apnea, in response to the Mayo Clini c. Approval for this indication could help strengthen insurance reimbursement for Zepbound and further reveal that weight reduction can provide greater than just cosmetic health improvements. Insurance coverage for Zepbound has been paltry since its launch within the U.S. market late last 12 months, due largely to its cost: its monthly list price is $1,060. “I think some of these numbers need to be taken note of by the insurance companies,” Jim Cramer said on CNBC on Wednesday. The energetic ingredient behind Zepbound and Mounjaro – often known as tirzepatide – is central to our investment thesis in Eli Lilly. Jim has long said that tirzepatide could develop into the best-selling drug of all time due to its ability to treat obesity and other diseases. It was first approved for the treatment of type 2 diabetes in May 2022 under the brand Mounjaro. Shares of Eli Lilly have taken the GLP-1 craze to latest heights lately. On March 4, the stock hit a record $800.78 per share, with a market cap of over $750 billion. LLY YTD Berg Eli Lilly YTD The obstructive sleep apnea data could open the door for Medicare to cover Zepbound for the condition, Morgan Stanley analysts said in a note to clients on Wednesday. Medicare prescription drug plans, often known as Part D, currently only cover obesity medications. Last month, the U.S. government agency that administers the seniors' health program allowed coverage for Novo's Wegovy since the drug is prescribed to scale back the danger of heart attacks and strokes. According to the Cleveland Clinic, obstructive sleep apnea is characterised by airway blockages that cause people to repeatedly stop respiratory during sleep and experience low oxygen levels within the blood, causing them to get up and begin respiratory again. This affects their ability to get quality sleep – and over time can result in other health complications similar to daytime sleepiness, heart damage and even sudden death. According to the National Council on Aging, obesity can contribute to the event of OSA, which is estimated to affect roughly 39 million adults within the United States. The current standard of take care of obstructive sleep apnea is positive airway pressure (PAP) devices, which help keep the patient's airway open during sleep. Eli Lilly released preliminary data from two late-stage studies on Wednesday, each of which showed that obese patients with moderate to severe obstructive sleep apnea saw improvements of their OSA over the course of a 52-week study. In one study, patients taking only Zepbound experienced a mean of 27.4 fewer times of restricted or completely blocked airflow per hour of sleep. The placebo patients only experienced a discount of 4.8 incidents per hour on average. In a second study, OSA patients who took Zepbound and used a PAP machine experienced a mean of 30.4 fewer events per hour, in comparison with six fewer within the placebo group. The results, which have yet to undergo peer review, met Wall Street's threshold to be considered a hit, Deutsche Bank analysts said in a note on Wednesday. Eli Lilly will present full data at an American Diabetes Association conference in late June. The popularity of GLP-1 has skyrocketed lately. They mimic a hormone within the gut to enhance blood sugar control, effectively suppressing appetite and thus resulting in weight reduction. The energetic ingredient in Novo Nordisk's Ozempic and Wegovy, semaglutide, works in an analogous solution to Lilly's tirzepatide. The key difference: Lilly's energetic ingredient targets a second hormone called GIP, which is believed to extend its effectiveness. LLY NVO Berg 2021-05-09 Eli Lilly vs. Novo Nordisk The stocks of each corporations were on fire. Eli Lilly has gained nearly 300% over the past three years, including a 28% gain year-to-date. Shares of Novo Nordisk are up around 243% over the past three years and up 19.5% thus far in 2024. At the identical time, these gains have worn out the performance of the S&P 500 and the healthcare sector index. The corporations currently have a duopoly within the GLP-1 market, which some Wall Street analysts estimate may very well be value $100 billion by the tip of the last decade. Despite the promise of treating other diseases, diabetes and obesity should account for the lion's share of GLP-1 sales. In a note to clients last month, Bank of America raised its 2030 sales forecast for tirzepatide to about $62 billion, including $54 billion for diabetes and obesity. Analysts forecast obstructive sleep apnea sales of $3 billion. (Jim Cramer's Charitable Trust is long-LLY. See a full list of stocks here.) As a subscriber to CNBC Investing Club with Jim Cramer, you’ll receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable foundation's portfolio. If Jim discussed a stock on CNBC television, he waits 72 hours after the trade alert is issued before executing the trade. THE INVESTING CLUB INFORMATION SET FORTH ABOVE IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY, ALONG WITH OUR DISCLAIMER. THERE ARE NO fiduciary duty or duty IN RECEIVING YOUR INFORMATION PROVIDED IN CONNECTION WITH THE INVESTMENT CLUB. NO SPECIFIC RESULTS OR PROFITS ARE GUARANTEED.
Eli LillyZepbound, the weight-loss drug, showed promise in treating sleep apnea — giving investors more confidence to proceed owning the world's most useful healthcare company even after it dragged down the S&P 500's performance over the past three years .
image credit : www.cnbc.com